Clinical-functional profile and correlation the time of injury with gait impairment in cases of myeloradiculopathy due to neuroschistosomiasis in the state of sergipe

Schistosoma affects about 200 million of poor people worldwide, with Schistosomamansoni being the leading cause of myeloradiculopathy syndrome that induces paraplegia, sexual and bladder dysfunction. In this context the weakness and muscular spasticity of the lower limbs directly affect the gait. Thus, the objective of this study was to present clinical-functional profileand to correlate the time of injury with gait impairment in cases of Myeloradiculopathy due to Neuroschistosomiasis in the State of Sergipe. It was a cross-sectional study between March 2017 and February 2018 of the seropositive cases for neuroeschistosomiasis diagnosed between 2010 and 2015 in a reference laboratory in Sergipe / Brazil. Of all individuals, ten (n = 10) agreed to redo the serology and clinical-functional exams linked to the gait. The clinical-neurological, neurovegetative, and functional variables were: American Spinal Cord Injury Association (ASIA); Functional Independence Measure (FIM per individual) and Functional Independence Measure (enviro FIM-motor tasksTM); Physical Activity Scale for Individuals with Physical Disabilities (PASIPD) with measurement of metabolic expenditure; and Ashworth Scale for spasticity. A descriptive analysis of the volunteers was used and Spearman's test R was applied for correlation. It was considered p <0.05 as significant in the values of r. As a result, adults were found 51.33 ± 11.88 years, with 4.2 ± 1.64 years of injury and 2.74 ± 1.56 years of positive serology for schistosomiasis. In ASIA, most were classified as incomplete lesions (ASIA D and E), and the clinical findings were 20% in Esficterian, 40% in sexual intercourse, 20% involuntary movement, 40% in heel knee, and patellar reflexes and Aquileo, both in 20%. In the functional evaluation of FIM, the mean and standard deviation were 125.4 ± 23.01, enviro FIM-motor tasksTM was 3.6 ± 0.84, Ashworth in the lower limbs as severe spasticity (3.5 ± 0.52), general PASIPD of 8.17 ± 9.10 and PASPD walking of 4.19 ± 4.18. When the correlation was made, it was verified that the lesion time was strongly influencing the increase of spasticity (r = 0.88, p = 0.009) and moderately the enviro FIM-motor tasksTM for walking (r = -0.68; p = 0.009). Thus, the individuals assisted by this laboratory present impaired walking associated with the time of injury, demonstrating chronicity of the lesion and indirect metabolic alteration. In this way it is necessary to direct these individuals to the clinical-neurofunctional treatment specific to their needs.